Literature DB >> 22160211

Comparison of oxidized porous silicon with bare porous silicon as a photothermal agent for cancer cell destruction based on in vitro cell test results.

Chongmu Lee1, Chanseok Hong, Jungkeun Lee, Mikwon Son, Soon-Sun Hong.   

Abstract

In the systematic administration of cancer, cancer markers are normally used to help the therapeutic agents access the cancer cells spontaneously. Therefore, it is essential to functionalize the surface of porous silicon (pSi) for cancer markers to attach well to pSi in systematic administration because most cancer markers does not attach easily to pSi. The thermal oxidation of pSi is adopted most widely as a surface functionalization technique for pSi. This study examined the photothermal properties and cancer cell-killing ability of oxidized pSi (pSiO). The temperature measurement and in vitro cell tests including the annexin V-fluorescein isothiocyanate (FITC) apoptosis assay tests, MTT assay tests, and Trypan blue cell death assay tests were performed to compare the photothermal properties and the cytotoxic effect of pSiO with those of pSi in combination with an 808-nm NIR laser. pSiO showed lower photothermal properties and a lower cell-death rate than bare pSi. On the other hand, the pSiO treatment used in combination with an NIR laser treatment showed a cytotoxic effect high enough to kill a considerable portion of the cancer cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160211     DOI: 10.1007/s10103-011-1032-9

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  19 in total

Review 1.  Hyperthermia in cancer therapy: current status.

Authors:  R L Anderson; D S Kapp
Journal:  Med J Aust       Date:  1990-03-19       Impact factor: 7.738

Review 2.  Photosensitized generation of singlet oxygen.

Authors:  Reinhard Schmidt
Journal:  Photochem Photobiol       Date:  2006 Sep-Oct       Impact factor: 3.421

3.  Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction.

Authors:  Nadine Wong Shi Kam; Michael O'Connell; Jeffrey A Wisdom; Hongjie Dai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-08       Impact factor: 11.205

4.  The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells.

Authors:  Rami G Azrak; Cheryl L Frank; Xiang Ling; Harry K Slocum; Fengzhi Li; Barbara A Foster; Youcef M Rustum
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

5.  Engineering the chemistry and nanostructure of porous silicon Fabry-Pérot films for loading and release of a steroid.

Authors:  Emily J Anglin; Michael P Schwartz; Valerie P Ng; Loren A Perelman; Michael J Sailor
Journal:  Langmuir       Date:  2004-12-07       Impact factor: 3.882

6.  Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers.

Authors:  Amy B Foraker; Rob J Walczak; Michael H Cohen; Tony A Boiarski; Carl F Grove; Peter W Swaan
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

7.  Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property.

Authors:  C Charnay; S Bégu; C Tourné-Péteilh; L Nicole; D A Lerner; J M Devoisselle
Journal:  Eur J Pharm Biopharm       Date:  2004-05       Impact factor: 5.571

Review 8.  Heating the patient: a promising approach?

Authors:  J van der Zee
Journal:  Ann Oncol       Date:  2002-08       Impact factor: 32.976

Review 9.  The current and potential role of hyperthermia in radiotherapy.

Authors:  J Overgaard
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

10.  Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology.

Authors:  J Overgaard; D Gonzalez Gonzalez; M C Hulshof; G Arcangeli; O Dahl; O Mella; S M Bentzen
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.